newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Requests Type A Meeting with FDA

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases,